Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
43.51
-0.54 (-1.23%)
Nov 21, 2024, 4:00 PM EST - Market closed
Kymera Therapeutics Employees
Kymera Therapeutics had 187 employees as of December 31, 2023. The number of employees increased by 20 or 11.98% compared to the previous year.
Employees
187
Change (1Y)
20
Growth (1Y)
11.98%
Revenue / Employee
$468,251
Profits / Employee
-$895,583
Market Cap
2.82B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 187 | 20 | 11.98% |
| Dec 31, 2022 | 167 | 26 | 18.44% |
| Dec 31, 2021 | 141 | 66 | 88.00% |
| Dec 31, 2020 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PACS Group | 32,433 |
| LifeStance Health Group | 9,325 |
| Warby Parker | 3,473 |
| LivaNova | 2,900 |
| HUTCHMED (China) | 1,988 |
| ACADIA Pharmaceuticals | 598 |
| TransMedics Group | 584 |
| Vericel | 314 |
KYMR News
- 16 days ago - Kymera Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 18 days ago - Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - GlobeNewsWire
- 4 weeks ago - Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - GlobeNewsWire
- 4 weeks ago - Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - GlobeNewsWire
- 6 weeks ago - Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewsWire
- 6 weeks ago - Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors - Seeking Alpha